行情

CERS

CERS

Cerus Corp
NASDAQ

实时行情|Nasdaq Last Sale

4.570
+0.090
+2.01%
盘后: 4.620 +0.05 +1.09% 19:30 01/24 EST
开盘
4.500
昨收
4.480
最高
4.689
最低
4.480
成交量
180.75万
成交额
--
52周最高
6.88
52周最低
3.700
市值
6.49亿
市盈率(TTM)
-8.9485
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CERS 新闻

  • 担忧污染饮用水德民众抗议特斯拉建厂 马斯克回应来了
  • 新浪美股.1小时前
  • 美国确诊第3例新型冠状病毒感染的肺炎病例
  • 中国新闻网.1小时前
  • 英国"脱欧"事务大臣:英国下个月将制定欧盟贸易目标
  • 新浪美股.2小时前
  • 离开武汉的500多万人都去了哪里?大数据告诉你
  • 第一财经日报.2小时前

更多

所属板块

医疗设备、用品及经销
-0.74%
医疗设备和用品
-0.90%

热门股票

名称
价格
涨跌幅

CERS 简况

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
展开

Webull提供Cerus Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。